The 70-gene signature (MammaPrint) accurately predicts distant breast cancer recurrence risk in older patients
PUBLICATION: SABCS 2020 AUTHORS: Iris Noordhoek, Esther Bastiaannet, Ersan Read More
Prediction of benefit from adjuvant pertuzumab by BluePrint RNA sequencing in the APHINITY trial
PUBLICATION: SABCS 2020 AUTHORS:Ian E Krop, Lorenza Mittempergher, Joseph N Read More
MammaPrint and BluePrint NGS Results are Robust and Accurate for Patients with Early Stage Breast Cancer
PUBLICATION: AMP 2020 AUTHORS: Douglas Kingma, Kasey Lawrence, Sahra Read More
ESMO 2020: UltraLow Data from the IKA Cohort
PUBLICATION: ESMO 2020 AUTHORS: Mark Opdam, Vincent van der Noort, Read More
ESMO 2020 – Hallmarks of Cancer
PUBLICATION: ESMO 2020 AUTHORS: Josien C. Haan, Rajith Bhaskaran, Lorenza Read More
Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial
PUBLICATION: European Journal of Cancer AUTHORS: Valesca P. Retel, Read More
I-SPY2: Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer
I-SPY2, JAMA Oncology, 2020 Authors: Yee et al.
Read More
Controlling Technical Variation Amongst 6693 Patient Microarrays of the Randomized MINDACT Trial
PUBLICATION: Communications Biology AUTHORS: Laurent Jacob, Anke Witteveen, Inès Beumer, Read More
ASCO 2020: Chemokine Signature
PUBLICATION: ASCO 20 AUTHORS: Hatem Soliman, Sangeetha Prabhakaran, Marilin Rosa, Read More
ASCO 2020: TNBC Subtype
PUBLICATION: ASCO 20 AUTHORS: Virginia G. Kaklamani, Cathy Graham, Karen Read More
